Key result
Rosuvastatin significantly reduced LDL-c by an average of 46.6 mg/dl at 12 weeks in heart transplant recipients with prior statin failure (P<0.001), with sustained long-term efficacy.
Why the study?
Does rosuvastatin improve lipid profiles in heart transplant recipients with hypercholesterolemia and therapeutic failure of other statin regimens?
Observational (n=30)
Does rosuvastatin improve lipid profiles in heart transplant recipients with hypercholesterolemia and therapeutic failure of other statin regimens?
Effect estimate: absolute reductions of -48.7 mg/dl, -46.6 mg/dl, and -0.9, respectively
p-value: p=< 0.001
Rosuvastatin effectively lowers LDL-c with an acceptable safety profile in heart transplant recipients who have failed previous statin therapies.
No takes yet. Share an insight, caveat, or question.
May support rosuvastatin after statin failure in heart transplant recipients; leaves open confirmation in randomized trials.
Barge‐Caballero et al. (2015) conducted an observational in heart transplant recipients with hypercholesterolemia and therapeutic failure of other statin regimens (n=30). rosuvastatin was evaluated on serum levels of total cholesterol, LDL-c, and TC/HDL-c ratio (absolute reductions of -48.7 mg/dl, -46.6 mg/dl, and -0.9, respectively, p=< 0.001). Rosuvastatin significantly reduced LDL-c by an average of 46.6 mg/dl at 12 weeks in heart transplant recipients with prior statin failure (P<0.001), with sustained long-term efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: